An overview of the rivastigmine 13.3 mg/24h transdermal patch as a treatment option for Alzheimer's disease
Fortea, Juan (Institut de Recerca Sant Pau)
Ferrer-Picón, Elena (Almirall (Barcelona))
Universitat Autònoma de Barcelona. Departament de Medicina

Data:	2025
Resum:	Introduction: Rivastigmine, a cholinesterase inhibitor, was first approved for the treatment of Alzheimer's disease (AD) dementia more than 20 years ago. Initially available as an oral formulation, a transdermal system was subsequently developed with the aim of improving tolerability while providing similar efficacy. Transdermal rivastigmine is approved for the treatment of severe AD as well as mild-to-moderate AD. Areas covered: Herein, the authors review randomized clinical trials, meta-analyses, and post-marketing observational studies involving the rivastigmine 13. 3 mg/24 h patch for the treatment of patients with AD. Expert opinion: Cholinesterase inhibitors are a mainstay of the symptomatic treatment of patients with AD. Rivastigmine is available as oral and transdermal formulations, with the latter providing improved tolerability and convenience while maintaining efficacy. The high-dose 13. 3 mg/24 h patch might offer benefits for some patients compared to the lower dose patch (4. 6 mg/24 h) in patients with mild-to-moderate or severe AD, showing improvements in daily functioning and global clinical status on top of the cognitive benefits. The ability to titrate up to a dose of 13. 3 mg/24 h provides an option for patients with severe AD or with an inadequate response to lower doses of rivastigmine.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Matèria:	Alzheimer’s disease ; Cholinesterase inhibitor ; Dementia ; Rivastigmine ; Transdermal patch
Publicat a:	Expert Review of Neurotherapeutics, Vol. 25, Num. 9 (2025) , p. 1119-1129, ISSN 1744-8360

DOI: 10.1080/14737175.2025.2527211
PMID: 40600688

12 p, 1.6 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats